Cocrystal forms of ((1s,2s,4r)-4-{4-[(1S)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof

a technology of pyrimidin and methyl sulfamate, which is applied in the field of crystal forms of ((1s, 2s, 4r)4 4(1s)2, 3dihydro1hinden1ylamino7hpyrrolo2, 3dpyrimidin7yl 2hydroxycyclopentyl) methyl sulfamate, can solve the problems of large-scale manufacturing of pharmaceutical compositions, affecting each step, and

Active Publication Date: 2020-09-03
TAKEDA PHARMA CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes new types of molecules called LCZ proteins which can bind to certain receptors on cells. They may help control how they function properly by controlling their activity.

Problems solved by technology

The technical problem addressed in this patent text relates to improving the stability and performance of certain compounds involved in treatments involving inflammation mediator systems. Specifically, current methods involve modifying the structure of the compounds themselves, but none offer a predictable way to make new drug forms.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cocrystal forms of ((1s,2s,4r)-4-{4-[(1S)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof
  • Cocrystal forms of ((1s,2s,4r)-4-{4-[(1S)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof
  • Cocrystal forms of ((1s,2s,4r)-4-{4-[(1S)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Microscale Cocrystal Formation of MLN4924

[0422]A cocrystal formation of MLN4924 was performed using twenty-five coformers including acetic acid, benzoic acid, camphoric acid, caproic acid, trans-cinnamic acid, ethylenediamine, fumaric acid, gentisic acid, D-glucuronic acid, glycolic acid, hippuric acid, DL-lactic acid, L-lysine, L-malic acid, malonic acid, DL-mandelic acid, meglumine, orotic acid, oxalic acid, piperazine, L-proline, L-pyroglutamic acid, saccharin, succinic acid, and vanillin. Crystallization techniques included evaporation, precipitation using an anti-solvent, slow cooling, vapor diffusion, slurrying, and liquid-assisted grinding. MLN4924 was used as starting material for the cocrystal formation experiments. XRPD data of isolated solids were compared to the pattern of MLN4924 free base, to each other, and to the patterns of respective coformers which are solid at ambient temperature.

[0423]Cocrystal formation experiments were first conducted on microscale in a 96-well p

example 2

Medium Scale Cocrystal Formation of MLN4924

[0424]Medium scale experiments then followed which allowed for a wider range of experimental techniques to be employed (Table 18). Isolated solids which exhibited a unique XRPD pattern were further characterized by proton spectroscopy to determine chemical composition and stoichiometry. Thermal analysis were conducted on selected solids.

[0425]Overall, sixty single or multi-step medium scale (˜50 mg to ˜200 mg) experiments were performed targeting various cocrystals of MLN4924 free base. Twenty coformers were studied including mono-, di-, and aromatic carboxylic acids (acetic acid, benzoic acid, trans-cinnamic acid, fumaric acid, gentisic acid, D-glucuronic acid, glycolic acid, hippuric acid, malonic acid, DL-mandelic acid, orotic acid, oxalic acid, L-pyroglutamic acid, and succinic acid), bases (ethylenediamine, meglumine, and piperazine), amino acids (L-lysine and L-proline), and saccharin. Crystallization techniques included evaporation, coo

example 3

Preliminary Evaluation of Selected MLN4924 Cocrystals

[0434]The aqueous solubility of new materials was estimated in water using a solvent addition method (Table 19). All new materials that were confirmed to contain a stoichiometric ratio of MLN4924 to coformer were estimated to have a solubility of less than 1 mg / mL.

TABLE 19Aqueous Solubility Estimates of MLN4924 Cocrystal CandidatesSolubilityMaterial testedCoformerX:Y aEstimateb(mg / mL)Form AGlycolic acid1:1 cForm BHippuric acid1:1Form FSaccharin  1:1 dForm GPiperazine2:1Form HGentisic acid  1:1 dForm JGentisic acid1:1Form LGentisic acid1:1Form MMalonic acid1:1Form NGentisic acid1:1 ca API:coformer stoichiometry as confirmed by proton NMR spectroscopy unless otherwise notedbValues are rounded to nearest whole number. If dissolution did not occur asdetermined by visual assessment value is reported as “cFew solids remainedd Ratio reported is from experimental conditions and was not confirmed by proton NMR

[0435]Each cocrystal was also

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Login to view more

Abstract

The present invention is directed to cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxcyclopentyl) methyl sulfamate of formula (I). The invention is also directed to methods of making cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate of formula (I). The invention is also directed to the pharmaceutical use of a cocrystal form as an E1 activating enzyme inhibitor, as well as a pharmaceutical composition comprising a cocrystal form. The invention is further directed to a method of treatment comprising administering a cocrystal form of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate of formula (I).

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products